// App-Quantinova.ai

: SABR in high-risk prostate cancer: Outcomes from two prospective clinical trials with and without elective nodal irradiation.

Researchers

Presenter

  • Yasir Alayed

Principal Investigators

  • Patrick Cheung

  • Danny Vesprini

  • Stanley K. Liu

  • William Chu

  • Hans T. Chung

  • Hima Bindu Musunuru

  • Melanie Davidson

  • Ananth Ravi

  • Ling Ho

  • Andrea Deabreu

  • Laura D'alimonte

  • Zeeba Bhounr

  • Liying Zhang

  • Kristina Commisso

  • Andrew Loblaw

Medical Centers

  • Odette Cancer Center, Sunnybrook Health Sciences Centre, Toronto, ON, Canada

  • Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada

  • Toronto-Sunnybrook Reg Cancer Centre, Toronto, ON, Canada

  • Deapertment of Radiation Oncology, Sunnybrook Health Sciences, University of Toronto, Toronto, ON, Canada

  • Sunnybrook Hospital, Radiation Oncology, University of Toronto, Toronto, ON, Canada

  • Sunnybrook Health Sciences Centre, Toronto, ON, Canada

Locations

  • Canada

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Prostate cancer

Biomarkers

  • Prostate specific antigen

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Prospective

Phase

  • NA

Study Id's

  • NCT01505075

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved